The state of Florida currently has 25 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Clinical Site 6, Tampa, Florida
Conditions: Atopic Dermatitis
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Recruiting
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/01/2025
Locations: Aclaris Study Site, Coral Gables, Florida +3 locations
Conditions: Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
Recruiting
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/30/2025
Locations: Attovia Clinical Site 109, Coral Gables, Florida
Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/27/2025
Locations: Clearlyderm Dermatology - West Boca /ID# 266323, Boca Raton, Florida +2 locations
Conditions: Atopic Dermatitis
A Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Investigational Site # 1, Coral Gables, Florida +2 locations
Conditions: Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
06/25/2025
Locations: Solutions Through Advanced Research, Jacksonville, Florida +1 locations
Conditions: Atopic Dermatitis, Eczema
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
06/25/2025
Locations: Clearlyderm Dermatology - West Boca /ID# 264923, Boca Raton, Florida +16 locations
Conditions: Atopic Dermatitis
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Sub-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Skin Care Research Boca Raton /ID# 272544, Boca Raton, Florida +3 locations
Conditions: Atopic Dermatitis
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Investigational Site #1, Coral Gables, Florida +1 locations
Conditions: Atopic Dermatitis
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Renaissance Research and Medical Group, Cape Coral, Florida +11 locations
Conditions: Atopic Dermatitis
Topical ENS-002 for Atopic Dermatitis in Adults
Recruiting
The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Encore Medical Research, Hollywood, Florida
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Recruiting
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
Gender:
ALL
Ages:
Between 3 months and 2 years
Trial Updated:
06/13/2025
Locations: Arcutis Clinical Study Site 207, Coral Gables, Florida +1 locations
Conditions: Atopic Dermatitis (Eczema)